medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2019, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2019; 18 (1)


Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity

Martínez-Valle F, Riveiro-Barciela M, Salcedo María-Teresa, Merino-Casabiel X, Fernández-Codina A, de Torres I, Esteban R, Buti M

Idioma: Ingles.
Referencias bibliográficas: 18
Paginas: 215-219
Archivo PDF: 267.06 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kamisawa T, Zen Y, Pillai S, Stone JH. Igg4- related disease. Lancet 2015; 385: 1460-71.

  2. Martinez-Valle F, Fernandez-Codina A, Pinal-Fernandez I, Orozco-Galvez O, Vilardell-Tarres M. Igg4-related disease: Evidence from six recent cohorts. Autoimmunity reviews 2017; 16: 168-72.

  3. Topazian M, Witzig TE, Smyrk TC, Pulido JS, Levy MJ, Kamath PS, Chari ST. Rituximab therapy for refractory biliary strictures in immunoglobulin g4-associated cholangitis. Clin Gastroenterol Hepatol 2008; 6: 364-6.

  4. Stone JH, Zen Y, Deshpande V. Igg4- related disesae. N Engl J Med 2012; 366: 539-51.

  5. Nakazawa T, Naitoh I, Hayashi K, Miyabe K, Simizu S, Joh T. Diagnosis of igg4-related sclerosing cholangitis. World J Gastroenterol 2013; 19: 7661-70.

  6. Ohara H, Okazaki K, Tsubouchi H, Inui K, Kawa S, Kamisawa T, Tazuma S, et al. Clinical diagnostic criteria of igg4- related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci 2012; 19: 536-42.

  7. Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, Levy MJ, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The mayo clinic experience. Gut 2013; 62: 1607-15.

  8. Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Desspande V, et al. Rituximab for igg4- related disease: A prospective, open-label trial. Ann Rheum Dis 2015; 74: 1171-7.

  9. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, Klöppel G, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012 ; 25: 1181-92.

  10. Fernandez-Codina A, Martinez-Valle F, Pinilla B, Lopez C, DeTorres I, Solans-Laque R, Fraile-Rodriguez G, et al. Igg4- related disease: Results from a multicenter spanish registry. Medicine 2015; 94: e1275.

  11. EASL clinical practice guidelines: Management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.

  12. Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: Primary sclerosing cholangitis. Am J Gastroenterol 2015; 110: 646-59.

  13. Karlsen TH, Schrumpf E, Boberg KM. Primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2010; 24: 655-66.

  14. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78.

  15. Li Y, Zhou L, Zhao X, Song W, Karunaratna N, Wang B. The importance of igg4 screening in patients diagnosed with primary sclerosing cholangitis in the past: A case rediagnosed as igg4-sc after 10 years. Medicine 2016; 95: e5628.

  16. Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, Chari ST, et al. International consensus guidance statement on the management and treatment of igg4- related disease. Arthritis Rheumatol 2015; 67: 1688-99.

  17. Nakazawa T, Shimizu S, Naitoh I. Igg4-related sclerosing cholangitis. Semin Liver Dis 2016; 36: 216-28.

  18. Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, Nakai Y, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56: 1719-24.




2020     |     www.medigraphic.com